Navigation Links
Genomics Likely to Replace Traditional Drug Therapies in Treating CHF
Date:4/17/2008

NEW YORK, April 17 /PRNewswire/ -- The market for congestive heart failure (CHF) drug treatments was estimated at $18 billion in 2007, and is expected to reach $30 billion by 2017, according to a new report by Kalorama Information, Congestive Heart Failure: Major World Markets, Volume I: Pharmaceutical Management. Growth is being driven by three factors: an increased incidence of CHF, the application of innovative technologies in search of targeted therapies which is creating opportunity for new entrants into this market, and physicians prescribing multi-drug regimens in response to the failure of traditional drugs to treat CHF.

CHF is a complex disorder for which prevention is more effective than treatment, and as part of the larger cardiovascular markets, it is mostly treated with drugs used to treat many other cardiovascular disorders. The lack of targeted treatments means drugs will continue to be applied liberally for prevention and sales will grow disproportionately to the CHF patient population.

"The future of CHF drug treatments lies in newer technologies such as biotechnology and genomics," notes Kenneth Krul, the report's analyst. "The identification of fetal genes associated with CHF, new treatments that address the endothelium and cell therapy to regenerate damaged heart muscle tissue present some promising areas."

The market for drugs to treat CHF will continue to be dominated by major pharmaceutical companies which supply product lines with broad cardiovascular applications. There are, however, many smaller companies focusing primarily on CHF and biotech, and their numbers are growing with the realization that this disease presents a major economic opportunity for which there is currently no adequate answer.

Kalorama Information's report Congestive Heart Failure: Major World Markets, Volume I: Pharmaceutical Management focuses on the market potential resulting from the application of current and advanced pharmaceutica
'/>"/>

SOURCE Kalorama Information
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
2. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
3. CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
4. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
5. WallSt.net (www.wallst.net) Announces Upcoming Interview With CEO of DNAPrint Genomics
6. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
7. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
8. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
9. BioNanoatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
10. BioNanomatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
11. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... NEW YORK , August 27, 2015 ... on enhancing image processing functions in the human vision system, ... Angeles point guard Chris Paul to ... basketball players who want to improve their real-life on-court performance. ... on the court, whether it is shooting a ball or ...
(Date:8/26/2015)... ... August 26, 2015 , ... ... today that a second US laboratory is to open in Manhattan, Kansas in ... continued partnership and long-term growth of research and development through collaboration with researchers ...
(Date:8/26/2015)... 2015  Platform therapeutic company Symic Biomedical, Inc. ... $1.5M Phase II SBIR grant from the National ... therapeutic agent to reduce arteriovenous fistula (AVF) failures, ... renal disease (ESRD) patients undergoing hemodialysis. The two-year ... and Digestive and Kidney Diseases (NIDDK), will allow ...
(Date:8/26/2015)... Florida , August 26, 2015 ... the biggest factors fueling the optimism in biotech,s ... M&A,s, collaborations and life sciences advancements.  Active biotechnology ... are Pressure BioSciences, Inc. (OTCQB: PBIO), Sequenom, Inc. ... SRPT ), Raptor Pharmaceutical Corp. (NASDAQ: ...
Breaking Biology Technology:Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 2Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 3MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 2New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 4New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 5New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 6New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 7
... 29 Pharmion Corporation,(Nasdaq: PHRM ) today ... has granted Fast Track designation for oral Azacitidine ... Track programs are designed to facilitate the development ... intended to treat serious or,life-threatening conditions and that ...
... with an overview of cardiovascular genetics ... ... 29 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: GEN),a company focused on ... virtually any disease or medical,condition, today announced that its co-founder ...
... Aug. 29 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,Inc. (NASDAQ: ... specialty pharmaceutical and,medical device company, today announced ... has given clearance to begin marketing the,Hemo-Stream(TM) ... developed by Rex Medical, LP, is the ...
Cached Biology Technology:Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 2Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 3Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 4Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 5Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 6GeneNews' Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book 2Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance 2Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance 3Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance 4
(Date:8/6/2015)... 2015  Today, U.S. Congressman Mike Honda ... to learn firsthand how Silicon Valley technologies can ... a world leader in multi-factor identity management and ... federal agencies and commercial organizations achieve new levels ... "The vast majority of network breaches can be ...
(Date:8/5/2015)... August 5, 2015 According to ... Management Market by Software, Services, Vertical (BFSI, Airport, IT & ... - Global Forecast to 2020", published by MarketsandMarkets, defines ... globally into various segments. The global PIAM Market is ... $546.2 Million by 2019, at a CAGR of 14.9 ...
(Date:8/4/2015)... 04, 2015 ... announced the addition of the "Digital ... Service), Sub-Segment (Computer Forensics, Network Forensics, Mobile ... Service, Vertical and Region - Global Forecast ... By Component (Hardware, Software, and ...
Breaking Biology News(10 mins):Rep. Honda to Visit Crossmatch in Redwood City 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
... University of Bergen, Norway have deduced how bony fishes ... filling their eggs with the water of life ?the ... genes causes the eggs to fill with vital water ... extant marine teleosts that showed an unprecedented radiation during ...
... Scientists at the MIT Media Lab have invented a ... yellow light, offering the prospect of controlling the haywire ... and Parkinson's disease. , Such diseases often must be ... MIT research could lead to the development of optical ...
... , professor of molecular biophysics and biochemistry at ... Foundation to expand research on the delivery of a targeted ... and his collaborator Zhiwei Hu have developed a way to ... thus destroying the tumors while leaving normal tissue unharmed. ...
Cached Biology News:How fish conquered the ocean 2How fish conquered the ocean 3MIT: Pulsing light silences overactive neurons 2Nanoparticles for delivery of prostate cancer treatment 2
Request Info...
... StabilZyme HRP Conjugate Stabilizer is an ... protein and other non-toxic stabilizing chemicals in ... 6.2 6.7. This product contains ... and 20 ppm Proclin 300 (Rohm and ...
Preparation Note: by a modification of the procedure of C.W. Hancher et al., Biotechnol. Bioeng. 11, 1055 (1969) Assay: ~ 20 A 260 /mg Solubility: water 10 mg/mL, clear, light-yellow Suitab tst...
Request Info...
Biology Products: